The role of interleukin-1β in pyoderma gangrenosum

JAAD Case Reports

Volumn 2, Issue 5, 2016, Pages 366-368

  Galimberti, Ricardo Luis ^a   Vacas, Aldana Soledad ^a   Bollea Garlatti, María Luz ^a   Torre, Ana Clara ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Autoinflammatory; canakinumab; interleukin 1 ; pyoderma gangrenosum

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; INTERLEUKIN 1BETA;

ADULT; ARTICLE; BLEEDING; CASE REPORT; CORTICOSTEROID THERAPY; EPITHELIZATION; FEMALE; GRANULATION TISSUE; HUMAN; LEG ULCER; MEDICAL HISTORY; MIDDLE AGED; PAIN; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; TENDON; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 84988934350     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.07.007     Document Type: Article

References (15)

1. 1 Wolff, K., Stingl, G., Feedberg, I.M., et al. Pyoderma gangrenosum., 6th ed Dermatología en Medicina General de Fitzpatrick, 2, 2005, Médica Panamericana, Mexico City, Mexico, 1088–1096.
2. 2 Brunsting, L.A., Goeckerman, W.H., O'sLeary, P.A., Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 22 (1930), 655–680.
3. 3 Bossi, G., Offidani, A., Síndromes cutáneos paraneoplásicos. Giannetti, A., Galimberti, R.L., (eds.) Tratado de dermatología, 2012, Piccin Nuova Libreria, Rome, Italy, 23–94.
4. 4 Sakiyama, M., Kobayashi, T., Nagata, Y., et al. Bullous pyoderma gangrenosum: a case report and review of the published work. J Dermatol 39 (2012), 1010–1015.
5. 5 Reichrath, J., Bens, G., Bonowitz, A., Tilgen, W., Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53 (2005), 273–283.
6. 6 Binuss, A.M., Qureshi, A., Li, V.W., Witerfield, L.S., Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 165 (2011), 1244–1250.
7. 7 Ruocco, E., Sangiuliano, S., Gravina, A.G., Miranda, A., Nicoletti, G., Pyoderma Gangrenosum: an updated review. J Eur Acad Dermatol Venereol 23 (2009), 1008–1017.
8. 8 Malieni, D., Torre, A.C., Baztan, M.C., Anselmi, C., Galimberti, R., Pioderma gangrenoso asociado a colitis ulcerosa tratado con infliximab. Dermatología Argentina 15:3 (2009), 191–195.
9. 9 Dinarello, C.A., Simon, A., Van der Meer, J.W.M., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11 (2012), 633–652.
10. 10 Geusau, A., Mothes-Luksch, N., Nahavandi, H., et al. Identification of a Homozygous PSTPIP1 Mutation in a Patient With a PAPA-Like Syndrome Responding to Canakinumab Treatment. JAMA Dermatol 149:2 (2013), 209–215.
11. 11 Brooklyn, T.N., Dunnill, M.G., Shetty, A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 55 (2006), 505–509.
12. 12 Jaeger, T., Andres, C., Grosber, M., et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa-rapid response to canakinumab (anti-IL-1b). Eur J Dermatol 23:3 (2013), 408–410.
13. 13 Ljung, T., Staun, M., Grove, O., et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF alfa; blockade with infliximab. Scand J Gastroenterol 37 (2002), 1108–1110.
14. 14 Kolios, A.G.A., Maul, J.T., Meier, B., et al. Canakinumab for steroid-refractory pyoderma gangrenosum. Br J Dertmatol 173 (2015), 1216–1223.
15. 15 Marzano, A.V., Fanoni, D., Antiga, E., et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 178:1 (2014), 48–56.